TNS1 Knockout U2OS Cell Line

Product Type:
In Stock Cell Lines
Species:
Homo sapiens (Human)
Tissue Source:
Bone
Disease:
Osteosarcoma
Host Cell:
U2OS
Gene Name:
TNS1
Inquire Now
✓ In stock
🚚 Ships next business day
Ask a Question

The TNS1 Knockout U2OS Cell Line is a CRISPR/Cas9-edited loss-of-function model for tensin 1 in U2OS human osteosarcoma cells. TNS1 bridges integrins to the actin cytoskeleton and recruits PTEN to suppress PI3K/AKT; its deletion disrupts adhesion and promotes migration. This cell line enables study of focal adhesion dynamics, integrin signaling, and tumor suppression. The p53 wild-type U2OS background supports drug testing in osteosarcoma and related cancers. Assays include immunofluorescence, migration/invasion, and phospho-signaling analysis.

Shipping Info: Cryopreserved in vials and shipped on dry ice

Disclaimer: For Research Use Only
Host CellU2OS
Sex of DonorFemale
Age15 years
Derived From SiteIn situ; Tibia
Gene NameTNS1
Gene IdentifierNCBI Gene ID 7145
MorphologyEpithelial-like
Growth ModeAdherent
StorageLiquid nitrogen (LN2)
Temperature37°C
Atmosphere5% CO₂
Sterility testingThe bacterial, yeast, and fungi are not detected in these cells by daily monitor.
Mycoplasma testingNegative for mycoplasma through PCR analysis

Intended Use: This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

Disclaimer: Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.

By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use.

This product is provided "AS IS". For Research Use Only. Not for human or animal therapeutic use.

Description

The TNS1 Knockout U2OS Cell Line is a CRISPR/Cas9-edited cell line in which the TNS1 gene has been disrupted to create a stable loss-of-function model in human U2OS osteosarcoma cells. This product eliminates full-length tensin 1 protein expression, enabling direct assessment of its roles in focal adhesion assembly, cytoskeletal organization, and integrin-mediated signaling pathways without reliance on transient suppression methods.

The parental U2OS cell line is an adherent epithelial-like human osteosarcoma line derived from a 15-year-old female. U2OS cells retain wild-type p53 and functional DNA damage response pathways, making them a widely used model for osteosarcoma biology, p53 signaling, and genomic stability. Their robust growth and reproducible behavior render them highly amenable to stable genetic editing and downstream functional assays, providing a clinically relevant host for interrogating TNS1-driven mechanisms.

Tensin 1 (TNS1) is a focal adhesion scaffold linking integrins (e.g., ITGB1, ITGAV) to the actin cytoskeleton and interacting with PTK2 (FAK), paxillin (PXN), talin-1 (TLN1), vinculin (VCL), and ??-actinin-1 (ACTN1). TNS1 is activated downstream of integrin?CSRC?CILK signaling and regulates RhoA. A critical function is recruitment of PTEN to adhesions, suppressing PI3K/AKT and migration; it also binds DLC1. Loss of TNS1 disrupts adhesion signaling, hyperactivating oncogenic pathways and enhancing motility.

In U2OS cells, TNS1 knockout profoundly alters focal adhesion dynamics and cytoskeletal architecture. Loss of PTEN localization to adhesions elevates basal PI3K/AKT activity, promoting survival and proliferation. Additionally, the absence of TNS1-mediated Rho GTPase regulation increases cell migration and invasion potential. These phenotypic changes recapitulate features of osteosarcoma aggressiveness and provide a tractable model to dissect tumor-suppressive roles of adhesion proteins. The wild-type p53 background further permits investigation of cross-talk between adhesion signaling and genomic stability pathways.

Researchers can employ this knockout cell line in immunofluorescence microscopy to visualize focal adhesion morphology, western blot analysis of phospho-signaling networks, transwell migration and invasion assays, co-immunoprecipitation to probe protein?Cprotein interactions, and quantitative adhesion assays. It is particularly suited for drug testing and mechanistic studies in osteosarcoma and other TNS1-implicated cancers, including breast, prostate, renal, and colorectal carcinomas. This clean genetic ablation enables precise interrogation of integrin-to-cytoskeleton communication and tumor suppression pathways. For further details, please contact Ascent Research.